Endocarditis following ocrelizumab in relapsing-remitting MS
Open Access
- 1 May 2020
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Neuroimmunology & Neuroinflammation
Abstract
Ocrelizumab is a monoclonal anti-CD20 antibody targeting B cells, which is authorized for relapsing-remitting MS (RRMS) and active primary progressive MS. Here, we report, to the best of our knowledge, the first case of infective endocarditis in a patient treated with ocrelizumab.Keywords
This publication has 6 references indexed in Scilit:
- Innate B Cells: the Archetype of Protective Immune CellsClinical Reviews in Allergy & Immunology, 2019
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisThe New England Journal of Medicine, 2017
- Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisThe New England Journal of Medicine, 2017
- Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III ProgramPLOS ONE, 2014
- Dual role for B-1a cells in immunity to influenza virus infectionThe Journal of Experimental Medicine, 2008
- Infective endocarditis complicating rituximab (anti-CD20 monoclonal antibody) treatment in an SLE patient with a past history of Libman–Sacks endocarditis: a case for antibiotic prophylaxis?Clinical Rheumatology, 2005